TMC-310911
| CAS No. | 1000287-05-7 | Cat. No. | BCP44275 |
| Name | TMC-310911 | ||
| Synonyms | ASC-09; TMC310911; ASC09; TMC 310911; ASC 09; | ||
| Formula | C38H53N5O7S2 | M. Wt | 755.99 |
| Description | TMC-310911 is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available [darunavir]. It is being investigated for use in HIV-1 infections. TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, making it a potentially desirable therapy for both treatment-naive and PI-experienced patients. TMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 caused by SARS-CoV-2. | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | HIV Protease | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.